A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 117



David R Spigel, Martin J Edelman, Kenneth O'Byrne, Luis Paz-Ares, Simonetta Mocci, See Phan, David S Shames, Dustin Smith, Wei Yu, Virginia E Paton, Tony Mok. J Clin Oncol 2017
Times Cited: 153




List of shared articles



Times cited

Novel biomarkers for the diagnosis and prognosis of gallbladder cancer.
Hong Ze Lin, Tao Zhang, Ming Yu Chen, Ji Liang Shen. J Dig Dis 2021
0

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.
Julia Lai-Kwon, Crescens Tiu, Abhijit Pal, Sachin Khurana, Anna Minchom. Crit Rev Oncol Hematol 2021
3

Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer.
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J Peters, Omidreza Firuzi. Crit Rev Oncol Hematol 2021
3

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.
Aaron C Tan, Tracy J Loh, Xue Lin Kwang, Gek San Tan, Kiat Hon Lim, Daniel S W Tan. Lung Cancer (Auckl) 2021
0

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Matthew Lee, Prantesh Jain, Feng Wang, Patrick C Ma, Alain Borczuk, Balazs Halmos. Expert Opin Ther Targets 2021
0

When the MET receptor kicks in to resist targeted therapies.
Marie Fernandes, Philippe Jamme, Alexis B Cortot, Zoulika Kherrouche, David Tulasne. Oncogene 2021
0

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.
Caroline E McCoach, Aiming Yu, David R Gandara, Jonathan W Riess, Daniel P Vang, Tiahong Li, Primo N Lara, Matthew Gubens, Frances Lara, Philip C Mack,[...]. JCO Precis Oncol 2021
1



A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models.
John O DaSilva, Katie Yang, Andres E Perez Bay, Julian Andreev, Peter Ngoi, Erica Pyles, Matthew C Franklin, Drew Dudgeon, Ashique Rafique, Anthony Dore,[...]. Clin Cancer Res 2020
3

Skipping Expected Mechanisms of MET-Mediated Oncogenesis.
Kurtis D Davies, Daniel T Merrick. J Thorac Oncol 2020
1

Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Carlo Genova, Giovanni Rossi, Marco Tagliamento, Erika Rijavec, Federica Biello, Luigi Cerbone, Lodovica Zullo, Francesco Grossi. Expert Rev Respir Med 2020
8

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
92

Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward.
Umberto Malapelle, Lucia Anna Muscarella, Pasquale Pisapia, Antonio Rossi. Expert Opin Investig Drugs 2020
5

Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma.
Xian Sun, Chia-Wei Li, Wei-Jan Wang, Mei-Kuang Chen, Hui Li, Yun-Ju Lai, Jennifer L Hsu, Paul B Koller, Li-Chuan Chan, Pei-Chih Lee,[...]. Am J Cancer Res 2020
5

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
M Schuler, R Berardi, W-T Lim, M de Jonge, T M Bauer, A Azaro, M Gottfried, J-Y Han, D H Lee, M Wollner,[...]. Ann Oncol 2020
26

Comprehensive review of targeted therapy for colorectal cancer.
Yuan-Hong Xie, Ying-Xuan Chen, Jing-Yuan Fang. Signal Transduct Target Ther 2020
120

Progress on treatment of MET signaling pathway in non-small cell lung cancer.
Xiaoqing Yu, Sizhe Yu, Yun Fan. Int J Clin Oncol 2020
1


MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
27

Targeting MET Dysregulation in Cancer.
Gonzalo Recondo, Jianwei Che, Pasi A Jänne, Mark M Awad. Cancer Discov 2020
19

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer.
Ramon Andrade De Mello, Nathália Moisés Neves, Giovanna Araújo Amaral, Estela Gudin Lippo, Pedro Castelo-Branco, Daniel Humberto Pozza, Carla Chizuru Tajima, Georgios Antoniou. J Clin Med 2020
3

Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaïd. Onco Targets Ther 2020
8

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Expert Opin Emerg Drugs 2020
3

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
114

The METeoric rise of MET in lung cancer.
Alex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, Solange Peters, Alfredo Addeo. Cancer 2020
7

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study.
Xue-Wen Liu, Xin-Ru Chen, Yu-Ming Rong, Ning Lyu, Chun-Wei Xu, Fang Wang, Wen-Yong Sun, San-Gao Fang, Jing-Ping Yuan, Hui-Juan Wang,[...]. Transl Oncol 2020
3

Update on emerging biomarkers in lung cancer.
Eric H Bernicker, Timothy Craig Allen, Phillip T Cagle. J Thorac Dis 2019
12